18F-FDG PET/MRI might be the diagnostic method of choice for Hodgkin lymphoma patients, as it combines significant metabolic information from PET with excellent soft-tissue contrast from MRI and avoids radiation exposure from CT. However, a major issue is longer examination times than for PET/CT, especially for younger children needing anesthesia. Thus, a targeted selection of suitable whole-body MRI sequences is important to optimize the PET/MRI workflow. Methods: The initial PET/MRI scans of 84 EuroNet-PHL-C2 study patients from 13 international PET centers were evaluated. In each available MRI sequence, 5 PET-positive lymph nodes were assessed. If extranodal involvement occurred, 2 splenic lesions, 2 skeletal lesions, and 2 lung lesions were also assessed. A detection rate was calculated dividing the number of visible, anatomically assignable, and measurable lesions in the respective MRI sequence by the total number of lesions. Results: Relaxation time-weighted (T2w) transverse sequences with fat saturation (fs) yielded the best result, with detection rates of 95% for nodal lesions, 62% for splenic lesions, 94% for skeletal lesions, and 83% for lung lesions, followed by T2w transverse sequences without fs (86%, 49%, 16%, and 59%, respectively) and longitudinal relaxation time-weighted contrast-enhanced transverse sequences with fs (74%, 35%, 57%, and 55%, respectively). Conclusion: T2w transverse sequences with fs yielded the highest detection rates and are well suited for accurate whole-body PET/MRI in lymphoma patients. There is no evidence to recommend the use of contrast agents.

Center for Modern Diagnostics MRI and PET MRI and Center for Nuclear Medicine and PET CT Bremen Germany

Charité Universitätsmedizin Berlin corporate member of Freie Universität Berlin Humboldt Universität zu Berlin and Department of Nuclear Medicine Berlin Institute of Health Berlin Germany

Department of Diagnostic and Interventional Radiology and Neuroradiology University Hospital Essen Essen Germany

Department of Imaging University Hospital Pilsen Pilsen Czech Republic

Department of Nuclear Medicine and Clinical Molecular Imaging University Hospital Tuebingen Tuebingen Germany

Department of Nuclear Medicine Faculty of Medicine and University Hospital Carl Gustav Carus Technische Universität Dresden Dresden Germany

Department of Nuclear Medicine Klinikum Rechts der Isar School of Medicine Technical University of Munich Munich Germany

Department of Nuclear Medicine Royal Children's Hospital Melbourne Victoria Australia

Department of Nuclear Medicine University Hospital Muenster Muenster Germany

Department of Nuclear Medicine University Hospital Zurich University of Zurich Zurich Switzerland

Department of Nuclear Medicine University of Leipzig Leipzig Germany

Department of Nuclear Medicine University of Leipzig Leipzig Germany;

Department of Pediatric Oncology Justus Liebig University Giessen Germany; and

Department of Radiology University of Halle Halle Saale Germany

Institute for Medical Informatics Statistics and Epidemiology University of Leipzig Leipzig Germany

Medical Faculty Martin Luther University of Halle Wittenberg Halle Saale Germany

Nuclear Medicine Unit Department of Medicine Padova University Hospital Padova Italy

Paediatric Radiology Department of Radiology University of Leipzig Leipzig Germany

UCL Institute of Nuclear Medicine University College London Hospitals London United Kingdom

Zobrazit více v PubMed

Verhagen MV, Menezes LJ, Neriman D, et al. . 18F-FDG PET/MRI for staging and interim response assessment in pediatric and adolescent Hodgkin lymphoma: a prospective study with 18F-FDG PET/CT as the reference standard. J Nucl Med. 2021;62:1524–1530. PubMed PMC

Herrmann K, Queiroz M, Huellner MW, et al. . Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer. 2015;15:1002. PubMed PMC

Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients. J Nucl Med. 2016;57:420–430. PubMed PMC

Ferdová E, Ferda J, Baxa J. 18F-FDG-PET/MRI in lymphoma patients. Eur J Radiol. 2017;94:A52–A63. PubMed

Huang B, Law MW, Khong PL. Whole‐body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–174. PubMed

Shah DJ, Sachs RK, Wilson DJ. Radiation-induced cancer: a modern view. Br J Radiol. 2012;85:e1166–e1173. PubMed PMC

Gatidis S, Gueckel B, La Fougère C, Schmitt J, Schaefer JF. Simultaneous whole-body PET-MRI in pediatric oncology: more than just reducing radiation? [in German]. Radiologe. 2016;56:622–630. PubMed

Kirchner J, Deuschl C, Grueneisen J, et al. . 18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed? Eur J Nucl Med Mol Imaging. 2017;44:1005–1013. PubMed

Kirchner J, Deuschl C, Schweiger B, et al. . Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI. Eur J Nucl Med Mol Imaging. 2017;44:1742–1750. PubMed

Second international inter-group study for classical Hodgkin lymphoma in children and adolescents. U.S. National Library of Medicine website. https://clinicaltrials.gov/ct2/show/NCT02684708. Published February 18, 2016. Updated May 13, 2021. Accessed October 31, 2022.

Kurch L, Mauz-Körholz C, Bertling S, et al. . The EuroNet paediatric Hodgkin network: modern imaging data management for real time central review in multicentre trials. Klin Padiatr. 2013;225:357–361. PubMed

Mauz-Körholz C, Landman-Parker J, Balwierz W, et al. . Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022;23:125–137. PubMed PMC

Latifoltojar A, Humphries PD, Menezes LJ, et al. . Whole-body magnetic resonance imaging in paediatric Hodgkin lymphoma: evaluation of quantitative magnetic resonance metrics for nodal staging. Pediatr Radiol. 2019;49:1285–1298. PubMed PMC

Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44:97–110. PubMed PMC

Cheson BD, Fisher RI, Barrington SF, et al. . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068. PubMed PMC

Schaefer JF, Berthold LD, Hahn G, et al. . Whole-body MRI in children and adolescents: S1 guideline. Rofo. 2019;191:618–625. PubMed

Hirsch FW, Sattler B, Sorge I, et al. . PET/MR in children: initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol. 2013;43:860–875. PubMed PMC

Grueneisen J, Sawicki LM, Schaarschmidt BM, et al. . Evaluation of a fast protocol for staging lymphoma patients with integrated PET/MRI. PLoS One. 2016;11:e0157880. PubMed PMC

Umutlu L, Beyer T, Grueneisen JS, et al. . Whole-body [18F]-FDG-PET/MRI for oncology: a consensus recommendation. Nuklearmedizin. 2019;58:68–76. PubMed

Hartung-Knemeyer V, Beiderwellen KJ, Buchbender C, et al. . Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging. Invest Radiol. 2013;48:290–294. PubMed

Arendt CT, Beeres M, Leithner D, et al. . Gadolinium-enhanced imaging of pediatric thoracic lymphoma: is intravenous contrast really necessary? Eur Radiol. 2019;29:2553–2559. PubMed

Klenk C, Gawande R, Tran VT, et al. . Progressing toward a cohesive pediatric 18F-FDG-PET/MR protocol: is administration of gadolinium chelates necessary? J Nucl Med. 2016;57:70–77. PubMed PMC

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834–841. PubMed

Radbruch A, Weberling LD, Kieslich PJ, et al. . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275:783–791. PubMed

Bezrukov I, Schmidt H, Gatidis S, et al. . Quantitative evaluation of segmentation- and atlas-based attenuation correction for PET/MR on pediatric patients. J Nucl Med. 2015;56:1067–1074. PubMed

Hofmann M, Bezrukov I, Mantlik F, et al. . MR-based attenuation correction for whole-body PET/MR: quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med. 2011;52:1392–1399. PubMed

Kwee TC, Basu S, Torigian DA, Nievelstein RAJ, Alavi A. Evolving importance of diffusion‐weighted magnetic resonance imaging in lymphoma. PET Clin. 2012;7:73–82. PubMed

Heacock L, Weissbrot J, Raad R, et al. . PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR. 2015;204:842–848. PubMed PMC

Giraudo C, Karanikas G, Weber M, et al. . Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging. J Magn Reson Imaging. 2018;47:1217–1226. PubMed

Spijkers S, Littooij AS, Kwee TC, et al. . Whole-body MRI versus an FDG-PET/CT-based reference standard for early response assessment and restaging of paediatric Hodgkin lymphoma: a prospective multicentre study. Eur Radiol. 2021;31:8925–8936. PubMed PMC

Littooij AS, Kwee TC, Barber I, et al. . Accuracy of whole-body MRI in the assessment of splenic involvement in lymphoma. Acta Radiol. 2016;57:142–151. PubMed

Punwani S, Cheung KK, Skipper N, et al. . Dynamic contrast‐enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease. Pediatr Radiol. 2013;43:941–949. PubMed

Mayerhoefer ME, Karanikas G, Kletter K, et al. . Evaluation of diffusion‐weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res. 2014;20:2984–2993. PubMed

Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 2010;30:269–291. PubMed

de Jong PA, Quarles van Ufford HM, Baarslag HJCT. 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR. 2009;192:745–753. PubMed

Picardi M, Soricelli A, Pane F, et al. . Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. Radiology. 2009;251:574–582. PubMed

Albano D, Patti C, Lagalla R, Midiri M, Galia M. Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging. 2017;45:1082–1089. PubMed

Krohmer S, Sorge I, Krausse A, et al. . Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol. 2010;74:256–261. PubMed

Schäfer JF, Gatidis S, Schmidt H, et al. . Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology. 2014;273:220–231. PubMed

Albano D, La Grutta L, Grassedonio E, et al. . Pitfalls in whole body MRI with diffusion weighted imaging performed on patients with lymphoma: what radiologists should know. Magn Reson Imaging. 2016;34:922–931. PubMed

Appenzeller P, Mader C, Huellner MW, et al. . PET/CT versus body coil PET/MRI: how low can you go? Insights Imaging. 2013;4:481–490. PubMed PMC

Hirsch FW, Sorge I, Vogel-Claussen J, et al. . The current status and further prospects for lung magnetic resonance imaging in pediatric radiology. Pediatr Radiol. 2020;50:734–749. PubMed PMC